All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2019 | ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM

By Emily Smith,Paul Richardson

Share:

Mar 15, 2018

At the 24th Congress of the European Hematology Association (EHA), Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, speaks to the Multiple Myeloma Hub about the results of the phase III ICARIA-MM trial of isatuximab + pomalidomide + dexamethasone compared to standard-of-care - pomalidomide + dexamethasone - for patients with relapsed/refractory multiple myeloma (RRMM).

 
Prof. Richardson highlights the high quality responses to the triplet regimen in relation to overall response and the primary endpoint of progression-free survival (approximately 12 months versus 6 months).
 
It was also highlighted that the triplet regimen was well tolerated and did not reduce the patient's quality of life. Whilst there was a higher rate of infection in the triplet arm, these were manageable. In subgroup analysis, all subgroups benefited.
 
Comparing isatuximab to daratumumab, Prof. Richardson highlighted some of the differences, including isatuximab's higher specificity to a different epitope, enhancing the apoptotic signal and leading to less complement activation and therefore less infusion reactions. Additionally, this means isatuximab can be given to patients with chronic obstructive pulmonary disease (COPD) and asthma which is significant.

ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM

More about...

PomalidomideDexamethasoneEHA 2019IsatuximabRelapsed/refractory multiple myelomaICARIA-MMAntibody therapyImmune modulatorsNuclear receptor agonistsEuropean Hematology AssociationPlasma cell dyscrasias

Your opinion matters

Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?

Newsletter

Subscribe to get the best content delivered to your inbox